Active Surveillance Study
Research type
Research Study
Full title
Active Surveillance Study for Prostate Cancer Management for Men at Higher Genetic Risk Compared with Men at No Known Higher Genetic Risk.
IRAS ID
317086
Contact name
Rosalind Eeles
Contact email
Sponsor organisation
The Institute of Cancer Research
Duration of Study in the UK
4 years, 7 months, 1 days
Research summary
Prostate cancer (PrCa) is the most common cancer in men in the Western world. In the United Kingdom (UK) there were over 52,000 new cases diagnosed in 2016-2018 and a lifetime risk of 1 in 8 for men born in the UK after 1960. However, its aetiology remains poorly understood. The substantial worldwide variation in incidence rates suggests that aetiology is multifactorial, and both genetic and lifestyle risk factors are important.
After diagnosis with PrCa some men go on to develop more aggressive forms of PrCa and in the metastatic setting the mortality is significant. It is estimated that from 2018 to 2040 PrCa mortality with double with 379,005 deaths worldwide. There remains an important clinical question to be answered: can we predict which men will go on to develop a more aggressive type of PrCa rather than a more indolent course of the disease, studies have been ongoing to try to answer this question.
The Active Surveillance study is a prospective study developed to look at the association of biomarkers with PrCa presentation and progression among men on Active Surveillance and stratify it by their genetic risk. This study will also investigate the incidence and progression by differing genetic risks.
The Active Surveillance study will collect samples to investigate the profile of plasma, serum, urine, stool and saliva biomarkers in men at a higher genetic risk of PrCa, who have been diagnosed with low risk PrCa and are undergoing Active Surveillance. It will also review the association of specific genetic profiles and biomarkers (biological samples – plasma, serum, urine, stool and saliva). These markers will be compared and contrasted with samples from men with no known increased genetic risk for PrCa.
REC name
Wales REC 4
REC reference
23/WA/0146
Date of REC Opinion
12 May 2023
REC opinion
Favourable Opinion